128 related articles for article (PubMed ID: 29237293)
1. CDH1 promoter methylation in patients with cervical carcinoma: a systematic meta-analysis with trial sequential analysis.
Liu G
Future Oncol; 2018 Jan; 14(1):51-63. PubMed ID: 29237293
[TBL] [Abstract][Full Text] [Related]
2. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
Zheng F; Yu H
Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of candidate methylation markers to detect cervical neoplasia.
Shivapurkar N; Sherman ME; Stastny V; Echebiri C; Rader JS; Nayar R; Bonfiglio TA; Gazdar AF; Wang SS
Gynecol Oncol; 2007 Dec; 107(3):549-53. PubMed ID: 17894941
[TBL] [Abstract][Full Text] [Related]
4. Predicting cervical intraepithelial neoplasia recurrence in HIV-infected and -noninfected women by detecting aberrant promoter methylation in the CDH1, TIMP3, and MGMT genes.
Teixeira da Costa Lodi C; Michelin MA; Miranda Lima MI; Murta EFC; Braga LDC; Montes L; Melo VH
Arch Gynecol Obstet; 2018 Nov; 298(5):971-979. PubMed ID: 30218185
[TBL] [Abstract][Full Text] [Related]
5. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
[TBL] [Abstract][Full Text] [Related]
6. [Death-associated protein kinase promoter (DAPK) hypermethylation in uterine cervical cancer and intraepithelial neoplasia in Uyghur nationality women].
Niyazi M; Liu XW; Zhu KC
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):31-4. PubMed ID: 22490852
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation and expression of CDH1 and susceptibility and prognosis of eyelid squamous cell carcinoma.
Wang YQ; Yuan Y; Jiang S; Jiang H
Tumour Biol; 2016 Jul; 37(7):9521-6. PubMed ID: 26790440
[TBL] [Abstract][Full Text] [Related]
8. [Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].
Zhong ZJ; Yang JX; Cao DY; Sun Y; Sun LL; Cheng XM; Chen J; Lang JH; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):196-200. PubMed ID: 22781071
[TBL] [Abstract][Full Text] [Related]
9. Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens.
Kim JH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C
Gynecol Oncol; 2010 Jan; 116(1):99-104. PubMed ID: 19836067
[TBL] [Abstract][Full Text] [Related]
10. The association between RARβ and FHIT promoter methylation and the carcinogenesis of patients with cervical carcinoma: A meta-analysis.
Shu R; He J; Wu C; Gao J
Tumour Biol; 2017 Jun; 39(6):1010428317709126. PubMed ID: 28639889
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between TAP gene promoter methylation and cervical lesions with HPV infection in Uyghur women].
Aikuer G; Jiao Z; Wu XC; Ma JQ; Abudla A; Hasim A
Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):438-42. PubMed ID: 22932452
[TBL] [Abstract][Full Text] [Related]
12. Association between Gene Promoter Methylation and Cervical Cancer Development: Global Distribution and A Meta-analysis.
El Aliani A; El-Abid H; El Mallali Y; Attaleb M; Ennaji MM; El Mzibri M
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):450-459. PubMed ID: 33441308
[TBL] [Abstract][Full Text] [Related]
13. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
14. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
15. Aberrant gene-specific DNA methylation signature analysis in cervical cancer.
Bhat S; Kabekkodu SP; Varghese VK; Chakrabarty S; Mallya SP; Rotti H; Pandey D; Kushtagi P; Satyamoorthy K
Tumour Biol; 2017 Mar; 39(3):1010428317694573. PubMed ID: 28351298
[TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of detection of tumor suppressor genes aberrant methylation in cervical carcinoma tissue].
Xu J; Wang HL; Lu GC; Wang ZJ; Lin X; Zhou HW
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):394-7. PubMed ID: 17697601
[TBL] [Abstract][Full Text] [Related]
17. [Promoter methylation of DAPK gene in cervical carcinoma].
Zhao XL; Meng ZY; Qiao YH; Zhang HL
Ai Zheng; 2008 Sep; 27(9):919-23. PubMed ID: 18799028
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of CDH1 and CDH13 DNA-methylation in serum of cervical cancer patients.
Abudukadeer A; Bakry R; Goebel G; Mutz-Dehbalaie I; Widschwendter A; Bonn GK; Fiegl H
Int J Mol Sci; 2012; 13(7):8353-8363. PubMed ID: 22942707
[TBL] [Abstract][Full Text] [Related]
19. Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma.
Banzai C; Nishino K; Quan J; Yoshihara K; Sekine M; Yahata T; Tanaka K;
Int J Clin Oncol; 2014 Feb; 19(1):127-32. PubMed ID: 23494221
[TBL] [Abstract][Full Text] [Related]
20. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]